Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
4.100
+0.090 (2.24%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Bicycle Therapeutics Employees
Bicycle Therapeutics had 288 employees as of December 31, 2025. The number of employees decreased by 17 or -5.57% compared to the previous year.
Employees
288
Change (1Y)
-17
Growth (1Y)
-5.57%
Revenue / Employee
$220,472
Profits / Employee
-$760,524
Market Cap
286.23M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Adagene | 128 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Surrozen | 44 |
| ALX Oncology Holdings | 43 |
BCYC News
- 5 weeks ago - Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting - Business Wire
- 2 months ago - Bicycle Therapeutics price target lowered to $12 from $13 at Jefferies - TheFly
- 2 months ago - Bicycle Therapeutics reports Q1 EPS (87c), consensus (65c) - TheFly
- 2 months ago - Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Business Wire
- 2 months ago - Bicycle Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Bicycle Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Bicycle Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting - Business Wire